Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Pharma Mar's Ecubectedin?
Ecubectedin is a small molecule commercialized by Pharma Mar, with a leading Phase II program in Sarcomas;Solid Tumor;Leiomyosarcoma;Liposarcoma;Synovial Sarcoma. According...
Ecubectedin by Pharma Mar for Small-Cell Lung Cancer: Likelihood of Approval
Ecubectedin is under clinical development by Pharma Mar and currently in Phase II for Small-Cell Lung Cancer. According to GlobalData,...
Risk adjusted net present value: What is the current valuation of Pharma Mar's Ecubectedin?
Ecubectedin is a small molecule commercialized by Pharma Mar, with a leading Phase II program in Ductal Carcinoma. According to...